Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Greensboro › NPI 1487212551
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $21.97M by Medicaid between Jul 2019 and Dec 2024, across 292 billing codes. Its largest line is 80061, Lipid panel — 5.8% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
GREENSBORO, NC 27410
33aNPI1487212551assigned 06/03/2019
33bProvider typeClinical Medical Laboratory
28Total paid$21.97M
24GClaims2,015,002
24DCodes billed292
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#11 of 128
Median peer was paid$268K
This provider vs. median82×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2019180,499$2.30M
2020372,730$5.02M
2021317,888$4.22M
2022281,575$2.83M
2023547,851$4.69M
2024incomplete314,459$2.92M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80061 Lipid panel 5.8% 131,577 122,641 $1.28M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 5.6% 57,981 54,059 $1.23M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.4% 49,791 43,561 $1.19M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.4% 49,620 43,443 $1.18M
80053 Comprehensive metabolic panel 4.3% 146,038 134,684 $954K
84443 Thyroid stimulating hormone (TSH) 3.6% 70,676 66,185 $792K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.3% 18,958 13,972 $715K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.9% 31,667 28,662 $648K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 2.9% 10,412 9,278 $643K
83036 Hemoglobin; glycosylated (A1C) 2.9% 93,985 87,782 $641K
80050 General health panel 2.8% 54,883 50,883 $625K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2.7% 13,124 10,295 $604K
280 more codes
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.7% 107,739 $600K
86003 2.2% 6,118 $492K
87086 Culture, bacterial; quantitative colony count, urine 2.0% 66,684 $442K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.7% 18,112 $378K
82607 1.3% 26,574 $283K
84439 1.2% 39,772 $271K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.2% 12,738 $268K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.2% 731 $262K
80074 1.2% 6,881 $262K
87088 1.2% 38,188 $257K
86480 1.1% 7,017 $248K
82728 1.0% 22,710 $221K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 6,721 $199K
86803 <1% 18,711 $197K
87070 <1% 23,134 $179K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 8,640 $173K
36415 Collection of venous blood by venipuncture <1% 100,449 $164K
87186 <1% 22,637 $162K
80048 Basic metabolic panel (calcium, ionized) <1% 28,112 $153K
82746 <1% 14,418 $152K
87510 <1% 8,943 $150K
83013 <1% 2,698 $146K
87660 <1% 9,009 $145K
87077 <1% 20,500 $138K
83970 <1% 6,016 $132K
85027 <1% 27,110 $128K
83550 <1% 20,233 $123K
84481 <1% 8,827 $122K
84153 <1% 9,292 $120K
86364 <1% 2,762 $108K
83540 <1% 22,914 $107K
86360 <1% 2,541 $107K
86235 <1% 1,808 $103K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 4,046 $102K
88142 <1% 5,848 $101K
87081 <1% 17,379 $100K
82570 <1% 30,443 $98K
84146 <1% 5,215 $96K
80055 <1% 3,752 $94K
86787 <1% 7,312 $89K
83880 <1% 4,299 $89K
82043 <1% 26,074 $87K
86850 <1% 9,301 $84K
81513 <1% 2,858 $79K
86592 <1% 21,343 $75K
87340 <1% 10,140 $74K
83735 <1% 16,225 $72K
84403 <1% 4,204 $71K
86008 <1% 1,349 $70K
84436 <1% 16,647 $69K
83001 <1% 4,661 $69K
84479 <1% 14,362 $66K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 275 $62K
86258 <1% 1,049 $60K
86696 <1% 3,533 $59K
87480 <1% 9,009 $58K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 224 $57K
83002 <1% 3,659 $56K
80164 <1% 4,600 $56K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 478 $56K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 1,177 $55K
86140 <1% 14,156 $54K
82784 <1% 5,234 $51K
82670 <1% 2,576 $50K
84702 <1% 6,684 $50K
80076 <1% 7,205 $49K
82785 <1% 3,389 $48K
88141 <1% 3,674 $48K
86376 <1% 3,801 $43K
83525 <1% 4,072 $42K
87147 <1% 7,917 $41K
87522 Neg quan hep c or qual rna <1% 2,185 $39K
87902 <1% 335 $37K
85652 <1% 16,641 $36K
83655 <1% 3,992 $35K
86695 <1% 3,054 $34K
84480 <1% 3,433 $33K
86706 <1% 4,354 $32K
81001 <1% 14,545 $32K
86708 <1% 3,372 $32K
83690 <1% 5,871 $31K
83516 <1% 3,916 $30K
86038 <1% 4,426 $30K
87536 <1% 787 $30K
82248 <1% 9,007 $29K
82274 <1% 2,169 $28K
86361 <1% 2,752 $28K
86800 <1% 2,137 $27K
84550 <1% 8,974 $27K
86704 <1% 4,187 $27K
82627 <1% 1,570 $27K
86665 <1% 2,339 $27K
87209 <1% 1,825 $27K
86231 <1% 911 $26K
80069 <1% 5,343 $26K
86769 <1% 1,026 $26K
82105 <1% 2,276 $26K
80081 <1% 802 $25K
86160 <1% 1,570 $25K
87150 <1% 840 $24K
87075 <1% 3,132 $24K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 196 $24K
86431 <1% 5,648 $23K
86900 <1% 8,046 $22K
86901 <1% 8,038 $22K
84144 <1% 1,517 $22K
86762 <1% 2,488 $22K
87650 <1% 1,150 $22K
85610 <1% 7,466 $22K
86200 <1% 2,439 $21K
88342 <1% 711 $21K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 441 $19K
86664 <1% 1,501 $19K
82550 <1% 3,676 $18K
86618 <1% 1,374 $18K
86225 <1% 1,843 $17K
87205 <1% 4,818 $17K
87563 <1% 442 $17K
82150 <1% 3,853 $17K
82950 <1% 3,920 $17K
87481 <1% 863 $16K
82977 <1% 3,287 $16K
84156 <1% 6,073 $16K
84270 <1% 1,198 $16K
86317 <1% 2,485 $15K
80178 <1% 2,342 $15K
87177 <1% 2,465 $14K
82533 <1% 1,051 $13K
84402 <1% 948 $13K
85379 <1% 1,864 $13K
81596 <1% 276 $13K
87449 <1% 1,650 $12K
82140 <1% 1,171 $12K
87427 <1% 1,224 $12K
87338 <1% 1,465 $12K
87045 <1% 1,944 $11K
82951 <1% 915 $11K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 499 $11K
84681 <1% 728 $11K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 441 $10K
86780 <1% 839 $10K
83520 <1% 1,143 $10K
87800 <1% 1,233 $9K
84100 <1% 3,527 $9K
85045 <1% 2,967 $9K
84703 <1% 1,376 $9K
85660 <1% 1,411 $8K
87324 <1% 924 $8K
87329 <1% 1,014 $8K
87046 <1% 1,575 $8K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 44 $8K
82677 <1% 337 $8K
88304 <1% 455 $8K
85730 <1% 1,739 $7K
80185 <1% 626 $7K
86812 <1% 290 $7K
83615 <1% 1,804 $7K
84466 <1% 766 $7K
87255 <1% 277 $6K
84450 <1% 2,181 $6K
82565 <1% 2,787 $6K
82947 <1% 1,999 $6K
88341 <1% 164 $6K
86039 <1% 1,140 $6K
86336 <1% 362 $6K
82247 <1% 1,772 $6K
87493 <1% 283 $6K
86147 <1% 232 $5K
84520 <1% 984 $5K
86015 <1% 208 $5K
85060 <1% 545 $5K
84154 <1% 358 $5K
80156 <1% 424 $5K
81003 <1% 2,956 $5K
84425 <1% 773 $5K
86705 <1% 1,068 $4K
85018 <1% 3,104 $4K
82310 <1% 2,080 $4K
82465 <1% 1,064 $4K
83090 <1% 740 $4K
80051 <1% 501 $4K
86141 <1% 524 $4K
84460 <1% 2,642 $4K
82330 <1% 529 $4K
83721 <1% 730 $4K
84165 <1% 337 $4K
86021 <1% 321 $4K
85014 <1% 2,154 $3K
81511 <1% 430 $3K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 146 $3K
83020 <1% 400 $3K
83630 <1% 430 $3K
82952 <1% 757 $3K
86593 <1% 658 $3K
81329 <1% 100 $3K
88312 <1% 74 $3K
83993 <1% 306 $3K
87899 <1% 381 $3K
86255 <1% 253 $2K
82652 <1% 145 $2K
84484 <1% 273 $2K
82040 <1% 852 $2K
86617 <1% 120 $2K
80197 <1% 322 $2K
80177 <1% 313 $2K
87799 <1% 115 $2K
83631 <1% 124 $2K
81025 <1% 349 $2K
86757 <1% 129 $1K
86359 <1% 61 $1K
82164 <1% 98 $1K
83718 <1% 132 $1K
82024 <1% 65 $1K
81015 <1% 403 $1K
87185 <1% 275 $1K
84132 <1% 387 $1K
87512 <1% 34 $960.25
86334 <1% 138 $950.51
86355 <1% 41 $925.78
83921 <1% 162 $891.72
82390 <1% 174 $822.96
86381 <1% 28 $792.76
84075 <1% 390 $791.94
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 17 $771.98
84478 <1% 223 $756.20
84432 <1% 55 $712.45
84305 <1% 63 $697.14
84155 <1% 496 $680.14
86304 <1% 71 $636.47
86870 <1% 31 $633.51
82103 <1% 113 $629.30
86709 <1% 97 $585.68
86308 <1% 124 $562.66
83519 <1% 73 $550.64
84630 <1% 97 $545.56
86146 <1% 28 $511.89
86735 <1% 40 $501.23
82107 <1% 26 $466.04
86644 <1% 29 $448.00
86765 <1% 39 $437.70
86645 <1% 27 $434.24
82088 <1% 26 $421.93
84445 <1% 26 $418.39
82378 <1% 31 $411.02
82542 <1% 27 $397.80
85007 <1% 147 $391.45
84244 <1% 31 $369.22
87807 <1% 29 $357.00
87210 <1% 99 $356.33
84295 <1% 222 $350.43
85041 <1% 282 $337.57
86357 <1% 12 $329.17
87517 <1% 14 $328.30
86036 <1% 37 $323.81
82525 <1% 48 $267.18
84134 <1% 31 $258.37
83021 <1% 48 $245.32
84207 <1% 15 $224.80
88300 <1% 26 $215.53
83498 <1% 14 $209.76
84590 <1% 41 $206.08
86886 <1% 45 $203.03
88112 <1% 16 $194.68
83014 <1% 37 $171.49
87328 <1% 27 $159.76
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 1,329 $139.18
83695 <1% 26 $131.11
80175 <1% 26 $131.00
83835 <1% 14 $126.22
87040 <1% 15 $126.06
81243 <1% 12 $118.94
85651 <1% 25 $103.54
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 111 $91.97
82787 <1% 12 $73.56
82374 <1% 12 $11.90
82435 <1% 12 $11.20
36416 <1% 36 $0.23
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) 0% 59 $0.00
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision 0% 18 $0.00
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) 0% 93 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under BOWLES, CHARLES

Full network →
ProviderLocationPaid
Quest Diagnostics LLCMarlborough, MA$209.74M
Quest Diagnostics of Pennsylvania, INC.Pittsburgh, PA$132.39M
Quest Diagnostics Clinical Laboratories INCSeattle, WA$109.23M
Quest Diagnostics Clinical Laboratories INCPortland, OR$21.85M
Quest Diagnostics of Pennsylvania INC.Buffalo, NY$20.20M
Quest Diagnostics Clinical Laboratories INCCollegeville, PA$12.52M
Solstas Lab Partners Group LLCGreensboro, NC$11.62M
Quest Diagnostics Incorporated MiFlint, MI$8.64M
Quest Diagnostics Clinical Laboratories INCTucker, GA$3.66M
Unilab CorporationWest Hills, CA$3.12M
Quest Diagnostics of Pennsylvania INC.Twinsburg, OH$2.56M
Quest Diagnostics Incorporated MDFalls Church, VA$936K
Quest Diagnostics LLCWallingford, CT$706K
Quest Diagnostics of Pennsylvania INC.North Syracuse, NY$492K
Solstas Lab Partners, LLCKnoxville, TN$455K
Quest Diagnostics Clinical Laboratories INCNorristown, PA$319K
Unilab CorporationSan Jose, CA$253K
Unilab CorporationOrange, CA$122K
Quest Diagnostics LLCStratford, CT$103K
Unilab CorporationBakersfield, CA$53K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.